|
81 |
Conducting a large, multi-site survey about patients’ views on broad consent: challenges and solutions
Enthalten in BMC medical research methodology Bd. 16, 24.11.2016, Nr. 1, date:12.2016: 1-11
|
|
|
|
82 |
Conquer fear: protocol of a randomised controlled trial of a psychological intervention to reduce fear of cancer recurrence
Enthalten in BMC cancer Bd. 13, 23.4.2013, Nr. 1, date:12.2013: 1-10
|
|
|
|
83 |
Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding
Enthalten in Nature Communications Bd. 15, 9.5.2024, Nr. 1, date:12.2024: 1-16
|
|
|
|
84 |
Core Set of Patient-Reported Outcome Measures for Measuring Quality of Life in Clinical Obesity Care
Enthalten in Obesity surgery Bd. 34, 15.7.2024, Nr. 8, date:8.2024: 2980-2990
|
|
|
|
85 |
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
Enthalten in Clinical pharmacokinetics Bd. 60, 23.7.2021, Nr. 9, date:9.2021: 1251
|
|
|
|
86 |
Correction: Inflammation and neutrophil extracellular traps in cerebral cavernous malformation
Enthalten in Cellular and molecular life sciences Bd. 79, 29.6.2022, Nr. 7, date:7.2022: 1-3
|
|
|
|
87 |
Correction: Reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy in Australia: outcomes of 12,000 tests
Enthalten in Genetics in medicine Bd. 20, 1.2.2018, Nr. 11, date:11.2018: 1485
|
|
|
|
88 |
Cortical Vision Impairment (CVI)-informed assessment and treatment of challenging behavior in a child with SCN2A-related disorder
Enthalten in Journal of neurodevelopmental disorders Bd. 16, 28.11.2024, Nr. 1, date:12.2024: 1-10
|
|
|
|
89 |
De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer
Enthalten in Journal of translational medicine Bd. 10, 8.3.2012, Nr. 1, date:12.2012: 1-10
|
|
|
|
90 |
De novo variants in the RNU4-2 snRNA cause a frequent neurodevelopmental syndrome
Enthalten in Nature Bd. 632, 11.7.2024, Nr. 8026, date:8.2024: 832-840
|
|
Administration
